TSTickerStarGet alerts
BTSGCompany update

BrightSpring Q2 2026 results: revenue +23% and Adjusted EBITDA +44% YoY; raises full-year 2026 guidance

Total Revenue was raised by +$375.0M to $15,100 million to $15,425 million (midpoint $15,262.5 million). BrightSpring Health Services reported Q2 2026 Net Revenue of $3,873 million (+23.0% YoY) and Adjusted EBITDA of $206 million (+44.2% YoY), with all results reflecting continuing operations following the March 30, 2026 divestiture of the Community Living business. The Amedisys and LHC acquisition contribution to 2026 Adjusted EBITDA was raised to approximately $35 million from approximately $30 million. Bright...

Published July 31, 2026 at 6:36 AM EDTBrightSpring Health Services, Inc.SEC filing
Share this story

Guidance updates

Total RevenueFull year 2026
$15,100 million to $15,425 million (midpoint $15,262.5 million)Prior $14,725 million to $15,225 million (midpoint $14,975 million) | raised | +$375.0M
Pharmacy Segment RevenueFull year 2026
$13,200 million to $13,500 million (midpoint $13,350 million)Prior $12,850 million to $13,300 million (midpoint $13,075 million) | raised | +$350.0M
Provider Segment RevenueFull year 2026
$1,900 million to $1,925 million (midpoint $1,912.5 million)Prior $1,875 million to $1,925 million (midpoint $1,900 million) | raised | +$25.0M
Total Adjusted EBITDAFull year 2026
$820 million to $845 million (midpoint $832.5 million)Prior $795 million to $825 million (midpoint $810 million) | raised | +$25.0M
Amedisys and LHC acquisition Adjusted EBITDA contributionFull year 2026
~$35 millionPrior ~$30 million | raised | +$5.0M

Forward guidance

Total RevenueFull year 2026
$15,100 million - $15,425 million17.0% to 19.5% growth (vs FY2025 continuing operations excluding Community Living)
Pharmacy Segment RevenueFull year 2026
$13,200 million - $13,500 million15.3% to 17.9% growth
Provider Segment RevenueFull year 2026
$1,900 million - $1,925 million29.7% to 31.4% growth
Total Adjusted EBITDAFull year 2026
$820 million - $845 million32.8% to 36.8% growth (vs FY2025 continuing operations excluding Community Living)
Amedisys and LHC acquisition Adjusted EBITDA contributionFull year 2026
~$35 million

Key takeaways

  • FY2026 Total Revenue guidance raised by +$375.0M to $15,100-$15,425M (midpoint $15,262.5M, 17.0%-19.5% growth); Total Adjusted EBITDA raised by +$25.0M to $820-$845M (midpoint $832.5M, 32.8%-36.8% growth).

  • Amedisys and LHC acquisition FY2026 Adjusted EBITDA contribution raised to approximately $35 million from approximately $30 million.

  • Q2 2026 results: Net Revenue $3,873M (+23.0% YoY); Adjusted EBITDA $206M (+44.2% YoY); Net income $87M vs $9M in Q2 2025; Adjusted EPS $0.45 vs $0.22.

  • Segment results both segments higher: Pharmacy Solutions revenue $3,407M (+22%) and segment EBITDA $180M (+44%); Provider Services revenue $466M (+30%) and segment EBITDA $75M (+33%).

  • Balance sheet: Leverage reduced to 2.15x at June 30, 2026 from 2.27x at March 31, 2026 following $300.0M First Lien Facility paydown; concurrent modification refinanced interest rates, resulting in interest savings.

  • Capital return: $60.0 million open-market repurchase of 1,026,465 shares completed concurrent with an underwritten secondary offering by KKR affiliates in June 2026.

  • All 2026 figures and growth rates reflect continuing operations after the March 30, 2026 Community Living divestiture; conference call July 31, 2026 at 8:30 a.m. ET, webcast at the linked primary source

Key metrics

Net RevenueQ2 2026
$3,873 million+23.0%
Net RevenueSix months ended June 30, 2026
$7,487 million+24%
Pharmacy Solutions RevenueQ2 2026
$3,407 million+22%
Provider Services RevenueQ2 2026
$466 million+30%
Pharmacy Solutions segment EBITDAQ2 2026
$180 million+44%
Provider Services segment EBITDAQ2 2026
$75 million+33%
Gross ProfitQ2 2026
$493 million+31.5%
Net incomeQ2 2026
$87 millionvs $9 million in Q2 2025

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Continue reading

All BTSG coverage

BTSG10-Q filing

BTSG 10-Q filed 2026-10-30 | Key takeaways

BTSGEarnings

BTSG Q3 2026 Total Revenue $4,213 million, Beat Guidance by +$397.4M

FFAICompany update

FFR October Robot Sales: 351 Units, Cumulative Reaches 1,168, Guidance Maintained at ~2,000 for FY2026

ISPCCompany update

iSpecimen Inc. Annual Meeting of Stockholders December 30, 2026

Follow BTSG in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert